Q1 Earnings Forecast for LVTX Issued By Leerink Partnrs

LAVA Therapeutics (NASDAQ:LVTX) – Equities research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for LAVA Therapeutics in a research note issued to investors on Thursday, December 12th. Leerink Partnrs analyst D. Graybosch forecasts that the company will post earnings per share of ($0.23) for the quarter. Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for LAVA Therapeutics’ current full-year earnings is ($1.28) per share. Leerink Partnrs also issued estimates for LAVA Therapeutics’ Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.22) EPS and Q4 2025 earnings at ($0.23) EPS.

Several other research firms have also recently weighed in on LVTX. JMP Securities reiterated a “market perform” rating and set a $6.00 price objective on shares of LAVA Therapeutics in a research report on Wednesday, December 11th. Leerink Partners reaffirmed a “market perform” rating and set a $2.00 price target (down from $11.00) on shares of LAVA Therapeutics in a research report on Thursday, December 12th. Finally, Citizens Jmp lowered shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 11th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $4.67.

LAVA Therapeutics Trading Up 2.0 %

Shares of NASDAQ LVTX opened at $1.04 on Monday. The business’s 50 day moving average is $1.66 and its 200-day moving average is $1.80. The firm has a market cap of $26.36 million, a P/E ratio of -1.01 and a beta of 0.43. LAVA Therapeutics has a 1-year low of $1.00 and a 1-year high of $6.47.

Institutional Investors Weigh In On LAVA Therapeutics

A number of large investors have recently bought and sold shares of the company. Virtu Financial LLC bought a new stake in shares of LAVA Therapeutics during the 3rd quarter worth approximately $32,000. Pathway Financial Advisors LLC lifted its stake in LAVA Therapeutics by 70.8% during the third quarter. Pathway Financial Advisors LLC now owns 102,500 shares of the company’s stock worth $170,000 after purchasing an additional 42,500 shares during the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of LAVA Therapeutics in the 2nd quarter valued at $55,000.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.